NanoViricides Reports Promising Results for NV-387 in Influenza A H3N2 Mouse Model
NanoViricides Reports Promising Results for NV-387 in Influenza A H3N2 Mouse Model
Key Takeaways (TLDR)
NV-387 provides significantly greater survival improvement compared to three approved influenza drugs, making it a powerful therapeutic option for treating severe influenza infections.
NV-387 was found effective in protecting lungs from damage in a lethally infected Influenza A H3N2 mouse model, resulting in lower immune system cell infiltration rates.
NV-387 has the potential to address current and emerging viral threats, offering a critical development in the field of antiviral therapies, making it a better place.
NV-387 oral treatment resulted in only about 31% lung infiltration by immune system cells, while intravenous treatment showed an even lower infiltration rate of about 22%.
Why it Matters
This news highlights the potential of NV-387 as a powerful therapeutic option for treating severe influenza infections and possibly other respiratory viral infections. It is a critical development in the field of antiviral therapies, especially in addressing both current and emerging viral threats.
Summary
NanoViricides CEO Dr Anil Diwan shared promising news about the company's ultra-broad-spectrum antiviral, NV-387. The antiviral was found to be effective in protecting lungs from damage in a lethally infected Influenza A H3N2 mouse model. NV-387 significantly protects the lungs of Balb/c mice lethally infected with the Influenza A H3N2 virus and resulted in a significantly greater survival improvement compared to three approved influenza drugs. These findings highlight the potential of NV-387 as a powerful therapeutic option for treating severe influenza infections and possibly other respiratory viral infections. This is a critical development in the field of antiviral therapies, especially in addressing both current and emerging viral threats.
This news story relied on a press release distributed by News Direct. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is NanoViricides Reports Promising Results for NV-387 in Influenza A H3N2 Mouse Model.